With the support of various departments such as the Ministry of Science and Technology, the State Health and Health Commission, and the State Food and Drug Administration, the antiviral drug remdesivir has completed the registration and approval of clinical trials, and the first batch of cases has been put in place. The first batch of severe pneumonia patients with new coronavirus infection will receive medication on February 6.
Prof. Cao Bin, the head of the clinical trial project of Redoxi and the deputy director of the Sino-Japanese Friendship Hospital, said that Redoxi is a drug under investigation by Gilead in the United States. Viruses and MERS coronaviruses have good antiviral activity, and clinical trials of Radesivir against Ebola coronavirus infection have been carried out abroad; recently, Chinese scholars reported that Ridesivir also has the 2019 new coronavirus at the cellular level. Good activity, but it still needs rigorous clinical trial evaluation before human application. At present, there is a lack of effective antiviral drugs for patients with new coronavirus infections, and we look forward to the clinical performance of redoxivir.
Academician Wang Chen, vice president of the Chinese Academy of Engineering and dean of the Chinese Academy of Medical Sciences, said at the launch meeting that people from all walks of life have expectations for this test, but whether it is effective or not, they still need to wait for the results of rigorous scientific tests.
According to reports, the preliminary preparations for drug transportation and group coding have been completed. The clinical trial of Redoxivir was led by the China-Japan Friendship Hospital and the Institute of Materia Medica of the Chinese Academy of Medical Sciences. The study will be conducted in a number of hospitals such as Wuhan Jinyintan Hospital that will receive patients with new coronavirus-infected pneumonia. , Using randomized, double-blind, placebo-controlled methods.
Online
+86-18153515027
BackToTop